GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024
GHAPPcast18 Okt 2024

GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024

Welcome back to the final installment of our three-part miniseries on Primary Biliary Cholangitis (PBC) from the GHAPP National 2024 Conference! In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss the most impactful updates in PBC management, treatment goals, and evolving clinical strategies.

A major highlight from this year’s meeting is the shifting treatment paradigm in PBC, moving beyond traditional Poise criteria to a more aggressive target of achieving completely normal alkaline phosphatase (ALKP) levels and a bilirubin of ≤0.6. Experts emphasize that new therapies, including seladelpar and elafibranor, are helping clinicians push treatment goals further, optimizing patient outcomes and disease management.


With the PBC treatment landscape evolving, the panel discusses how the mindset around ALKP reduction has changed, underscoring the importance of setting normalization as the primary goal rather than just achieving a modest reduction. With new and emerging therapies, there is growing excitement about more effective disease control and improved long-term prognosis for patients with PBC.


Watch now to stay ahead on the latest PBC treatment advancements, and don’t forget to check out the full miniseries! For more resources, visit GHAPP.org or download the GHAPP ACE app.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Maj 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Maj 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Maj 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Maj 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
sexnoveller-deluxe
angestpodden
rss-vuxna-pa-latsas
not-fanny-anymore
inga-beiga-morsor
johannes-hansen-podcast
rss-viktmedicinpodden
sa-in-i-sjalen
rss-the-house-podcast-3
sova-med-dan-horning
brottarbroder
rss-sjalsligt-avkladd
sex-pa-riktigt-med-marika-smith
rss-jossan-nina
efterlevandepodden
rss-activation-podcast
rss-paus-guidade-meditationer
rss-basta-livet